Literature DB >> 29982382

Epidemiology of Meningococcal Disease Outbreaks in the United States, 2009-2013.

Sarah A Mbaeyi1, Amy Blain1, Melissa J Whaley1, Xin Wang1, Amanda C Cohn1, Jessica R MacNeil1.   

Abstract

Background: Although the incidence of meningococcal disease is low in the United States, outbreaks remain a serious public health concern. In this evaluation, we identify and describe outbreaks of meningococcal disease.
Methods: A retrospective review of all meningococcal disease cases reported from 1 January 2009 to 31 December 2013 was performed by state health departments and the Centers for Disease Control and Prevention to identify meningococcal disease outbreaks. An outbreak was defined as ≥2 primary cases of the same serogroup within <3 months in an organization, or a ≥2-fold increase in disease rates in a community.
Results: From 2009 to 2013, a total of 3686 cases of meningococcal disease were reported in the United States. Among these, 180 primary cases (4.9%) occurred as part of 36 outbreaks (17 organization-based and 19 community-based). Serogroup B accounted for 8 (47.1%) of the organization-based outbreaks, including 6 of 8 university outbreaks. Serogroup C accounted for 10 (52.6%) of the community-based outbreaks, including both of 2 outbreaks identified among men who have sex with men. Organization- and community-based outbreaks differed in predominant serogroup, age distribution of cases, and clinical syndrome. Among 33 outbreaks with known information, a vaccination and/or expanded chemoprophylaxis campaign was conducted in 16 (48.5%). Conclusions: Outbreak-associated cases account for approximately 5% of all meningococcal disease cases in the United States. Serogroup B is the primary cause of organization-based outbreaks, with the majority of university outbreaks due to serogroup B, and serogroup C is the primary cause of community-based outbreaks.

Entities:  

Mesh:

Year:  2019        PMID: 29982382     DOI: 10.1093/cid/ciy548

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

Review 2.  Meningococcal disease and vaccination in college students.

Authors:  Sarah Schaffer DeRoo; Rachel G Torres; Linda Y Fu
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

Review 3.  Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.

Authors:  Mark R Cullen; Adina R Lemeshow; Leo J Russo; David M Barnes; Yaa Ababio; Aida Habtezion
Journal:  Healthcare (Basel)       Date:  2022-03-23

4.  University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.

Authors:  Heidi M Soeters; Lucy A McNamara; Amy E Blain; Melissa Whaley; Jessica R MacNeil; Susan Hariri; Sarah A Mbaeyi
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

Review 5.  Meningococcal pneumonia: a review.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Pneumonia (Nathan)       Date:  2019-08-25

6.  Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B in a nursery school, Wallonia, Belgium, 2018.

Authors:  Stéphanie Jacquinet; Wesley Mattheus; Sophie Quoilin; Chloé Wyndham-Thomas; Charlotte Martin; Dimitri Van der Linden; André Mulder; Julie Frère; Carole Schirvel
Journal:  Euro Surveill       Date:  2022-03

Review 7.  Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.

Authors:  Sandra Guedes; Isabelle Bertrand-Gerentes; Keith Evans; Florence Coste; Philipp Oster
Journal:  BMC Public Health       Date:  2022-02-23       Impact factor: 3.295

8.  Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Authors:  Andrew Stawasz; Liping Huang; Paige Kirby; David Bloom
Journal:  Front Public Health       Date:  2020-07-10

9.  Insights on Population Structure and Within-Host Genetic Changes among Meningococcal Carriage Isolates from U.S. Universities.

Authors:  Sandeep J Joseph; Nadav Topaz; How-Yi Chang; Melissa J Whaley; Jeni T Vuong; Alexander Chen; Fang Hu; Susanna E Schmink; Laurel T Jenkins; Lorraine D Rodriguez-Rivera; Jennifer D Thomas; Anna M Acosta; Lucy McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang
Journal:  mSphere       Date:  2020-04-08       Impact factor: 4.389

10.  Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.

Authors:  Eric Richardson; Kathleen A Ryan; Robert M Lawrence; Christopher A Harle; Alyson Young; Melvin D Livingston; Amit Rawal; Stephanie A S Staras
Journal:  J Community Health       Date:  2021-01-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.